DREAMM-10

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

May 20, 2020 → Oct 19, 2026

Cited window

Feb 7, 2024 → Oct 17, 2026

Retrieved

Oct 24, 2026

Title

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Registry

NCT06679101

Study IDs

214828 · 2024-516030-35 (CTIS)

Sponsor

GlaxoSmithKline

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

520 estimated

Start

2024-12-16 actual

Primary completion

2031-04-28 estimated

Primary endpoint

PFS

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 57 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –556 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative survey of HCP opinion. Repeated statements and reposts do not establish independent agreement.
• –No publication reporting DREAMM-10 outcomes was identified, and a full trial protocol was not available. Supporting-study findings and prospective expectations cannot be read as target-trial results.
• –Some potentially relevant discussion of sequencing, community uptake, financial burden and comparative efficacy was not fully assessed. The report may therefore omit consequential qualifications or additional views.
• –Coverage based on trial names and related terminology may miss unnamed references or alternative transcriptions.
• –Some recorded passages were available only in their original transcript, leaving uncertainty about exact wording or speaker identification. Unidentified speakers remain unnamed.
• –Regulatory documents were not comprehensively assessed. Monitoring and access statements reflect their source, date and jurisdiction, not a verified current standard everywhere.
• –Small dose cohorts, differing follow-up, different regimens and inconsistent MRD or ocular-assessment denominators limit comparisons across the supporting studies.
• –Some speakers described different DREAMM-10 dosing intervals. The reviewed material does not resolve those differences.
• –Transplant-ineligible, transplant-deferred and quad-eligible populations are not interchangeable; related quadruplet discussions do not establish the same benefit–risk balance for all DREAMM-10 patients.

How reports are built and checked: Methods.

Last checked for new commentary Oct 25, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.